Clinical-stage biopharma developing oral therapies for retinal vascular diseases
| Date | Round | Amount |
|---|---|---|
| Nov 2022 | Seed Copenhagen biopharma Breye Therapeutics raised a EUR4M seed round led by Novo Holdings and Sound Bioventures to advance its lead asset to Phase 1b. | $4.2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.